Small Interfering RNA (siRNA) Therapeutics Market by Type, Applications, Region – Global Market Size Estimation, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2032
Overview
Global Small Interfering RNA (siRNA) Therapeutics Market size was valued at USD 14.89 Bn in 2025 and is expected to reach USD 46.03 Bn by 2032, at a CAGR of 17.5 % during a forecast period.
Small Interfering RNA (SIRNA) Therapeutics Market Overview:
Small Interfering RNAs, also called as silencing RNA, is a class of double stranded non-coding RNA molecules. These are the most widely used nucleic acid based sequence for interfering expression of specific genes. The siRNAs help to recognize unique pathways and to validate targets for various life threatening diseases such as cancer, AIDS etc.
To Know About The Research Methodology :- Request Free Sample Report
Small Interfering RNA (SIRNA) Therapeutics Market Dynamics:
Higher efficiency of the siRNA compared to earlier reverse genetic technologies is considered to be the prime factor driving the market growth.
siRNA has widespread applications; it is used to assess cellular phenotypes, including cytokinesis, apoptosis, insulin signalling and cell differentiation. The high potential of gene silencing of siRNA has resulted in many target-specific therapeutic applications for validating targets in cancer, HIV infection, hepatitis, etc. Rising number of clinical trials, short duration of pre-clinical development, rising government funding for research and developmental activities, well-established healthcare infrastructure are key drivers which augment the market growth.
Additionally, as cancer remains a leading cause of global death, small interfering RNAs (siRBAs) emerge as significant advancements.They play a major role in regulating gene expression through a process known as RNA interference (RNAi), contributing favorably market expansion.
The report highlights profiles of fifteen key players operating in various regions. It thoroughly examines market leaders, followers, and newcomers from a non-cooperating investor perspective in estimating the market size. The study focuses on regional influences on costs, the availability of advance technology, and specific researches and developements.
Small Interfering RNA (siRNA) Therapeutics Market Segment Analysis:
By Type – Segment Overview (2025)
The nanoparticle-based systemic therapy segment is expected to hold the maximum market share in 2025. This dominance is driven by improved delivery efficiency, enhanced stability of siRNA molecules, and targeted gene silencing capabilities. Nanoparticle carriers protect siRNA from enzymatic degradation and improve cellular uptake, resulting in better therapeutic outcomes. Growing adoption of lipid nanoparticles in commercialized siRNA drugs and increasing clinical trials further strengthen this segment. Additionally, technological advancements in nanocarrier design and rising investments from pharmaceutical companies are accelerating product development, thereby supporting higher revenue generation in 2025.
By Therapeutic Area – Segment Overview (2025)
The oncology segment is projected to account for the largest market share in 2025. Rising global cancer prevalence and increasing demand for targeted molecular therapies are key growth drivers. siRNA therapeutics enable precise gene silencing of cancer-causing mutations, offering improved treatment specificity with reduced side effects compared to conventional chemotherapy. Expanding research pipelines, strategic collaborations, and regulatory approvals for RNA-based cancer treatments further contribute to segment growth. Moreover, significant funding for oncology-focused research and strong commercialization potential make oncology the leading revenue-generating therapeutic area within the siRNA therapeutics market in 2025..
Small Interfering RNA (siRNA) Therapeutics Market Regional Insights:
North America is expected to hold the maximum share of the Small Interfering RNA (siRNA) Therapeutics Market in 2025. The dominance is attributed to strong biotechnology infrastructure, high healthcare expenditure, and early adoption of advanced RNA-based therapies. The presence of leading players such as Alnylam Pharmaceuticals and Arrowhead Pharmaceuticals significantly supports regional growth. Additionally, favorable regulatory frameworks, increasing clinical trials, and robust research funding in the United States drive innovation. Growing prevalence of chronic and genetic disorders further boosts demand for targeted siRNA therapeutics across the region.
Asia Pacific is projected to be the fastest-growing region in the Small Interfering RNA (siRNA) Therapeutics Market in 2025. Rapid expansion of biotechnology industries in China, Japan, South Korea, and India is driving regional growth. Increasing government support for genomic research, rising healthcare investments, and growing awareness of advanced RNA-based treatments contribute significantly to market expansion. Moreover, expanding clinical trial activities and partnerships between global pharmaceutical companies and regional biotech firms are accelerating innovation. The large patient pool and improving healthcare infrastructure further strengthen Asia Pacific’s growth potential in 2025.
The report also helps in understanding the global Small Interfering RNA (siRNA) Therapeutics Market dynamics and structure by analyzing the market segments and project the Global market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global market make the report investor’s an guide.
Small Interfering RNA (siRNA) Therapeutics Market Report: Inquire before buying
| Global Small Interfering RNA (siRNA) Therapeutics Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | 14.89 USD Bn |
| Forecast Period 2026-2032 CAGR: | 17.5% | Market Size in 2032: | 46.03 USD Bn |
| Segments Covered: | By Type | Liposome Based Systemic Therapy Nanoparticle Based Systemic Therapy Other |
|
| By Route of Administration | Intravenous (IV) Subcutaneous Intrathecal Topical Others |
||
| By Application | Hospitals Research Institutions Pharmaceutical & Biotechnology Companies Academic Institutions Other |
||
Small Interfering RNA (siRNA) Therapeutics Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Key Players/Competitors Profile, Covered in Global Small Interfering RNA (siRNA) Therapeutics Market Report, From A Strategic Perspective.
1. GE Dharmacon
2. OPKO Health, Inc.
3. Alnylam Pharmaceuticals
4. Arrowhead Pharmaceuticals
5. Sanofi Genzyme
6. Genecon Biotechnologies Co., Ltd.
7. Arbutus Biopharma Corporation
8. Silence Therapeutics plc
9. Sylentis S.A.
10. Olix Pharmaceuticals, Inc.
11. GlaxoSmithKline plc
12. Ionis Pharmaceuticals, Inc.
13. Benitec Biopharma Ltd
14. Bio-Path Holdings, Inc.
15. Calando Pharmaceuticals
16. Dicerna Pharmaceuticals, Inc.
17. Quark Pharmaceuticals, Inc.
18. Sirnaomics, Inc.
19. Tekmira Pharmaceuticals
20. RXi Pharmaceuticals Corporation
21. Novartis AG
22. Roche Holding AG
23. Pfizer Inc.
24. Moderna, Inc.
25. Arcturus Therapeutics Holdings Inc.